Oxford Immunotec Global Plc (OXFD) Drops 5.04% on January 04

Equities Staff  |

Oxford Immunotec Global Plc (OXFD) was one of the Russell 2000's biggest losers for Monday January 04 as the stock slid 5.04% to $10.92, a loss of $-0.58 per share. Starting at an opening price of $11.43 a share, the stock traded between $10.81 and $11.96 over the course of the trading day. Volume was 97,308 shares over 454 trades, against an average daily volume of 43,343 shares and a total float of 22.54 million.

The losses send Oxford Immunotec Global Plc down to a market cap of $246.12 million. In the last year, Oxford Immunotec Global Plc has traded between $15.04 and $10.41, and its 50-day SMA is currently $12.42 and 200-day SMA is $13.18.

Oxford Immunotec Global PLC is a commercial-stage diagnostics company. It is engaged in developing and commercializing proprietary tests for the management of immune-regulated conditions. Its platform includes T-SPOT technology platform.

Oxford Immunotec Global Plc is based out of Abingdon, and has some 267 employees. Its CEO is Peter Wrighton-Smith.

For a complete fundamental analysis analysis of Oxford Immunotec Global Plc, check out Equities.com’s Stock Valuation Analysis report for OXFD. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Crypto World in Review: Taking in the Good with the Bad

A lot happened in the cryptocurrency industry this week.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.